<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Adalimumab for maintenance of remission in Crohn's disease - Townsend, CM - 2020 | Cochrane Library</title> <meta content="Adalimumab for maintenance of remission in Crohn's disease - Townsend, CM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012877.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Adalimumab for maintenance of remission in Crohn's disease - Townsend, CM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012877.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012877.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Adalimumab for maintenance of remission in Crohn's disease" name="citation_title"/> <meta content="Cassandra M Townsend" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Tran M Nguyen" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Jeremy Cepek" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Mohamad Abbass" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Claire E Parker" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="jmacdon1@uwo.ca" name="citation_author_email"/> <meta content="Reena Khanna" name="citation_author"/> <meta content="Vipul Jairath" name="citation_author"/> <meta content="Brian G Feagan" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012877.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/05/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012877.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012877.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012877.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adalimumab [adverse effects, *therapeutic use]; Anti-Inflammatory Agents [adverse effects, *therapeutic use]; Azathioprine [therapeutic use]; Crohn Disease [*drug therapy]; Drug Administration Schedule; Immunosuppressive Agents [therapeutic use]; Maintenance Chemotherapy [*methods, statistics &amp; numerical data]; Mercaptopurine [therapeutic use]; Mesalamine [therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha [antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012877.pub2&amp;doi=10.1002/14651858.CD012877.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012877\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012877\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012877.pub2",title:"Adalimumab for maintenance of remission in Crohn\u0027s disease",firstPublishedDate:"May 16, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012877.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012877.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012877.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012877.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012877.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012877.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012877.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012877.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012877.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012877.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5017 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012877.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/appendices#CD012877-sec-0077"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/supinfo/CD012877StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/supinfo/CD012877StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Adalimumab for maintenance of remission in Crohn's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0004">Cassandra M Townsend</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0005">Tran M Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0006">Jeremy Cepek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0007">Mohamad Abbass</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0008">Claire E Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>John K MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0010">Reena Khanna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0011">Vipul Jairath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information#CD012877-cr-0012">Brian G Feagan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information/en#CD012877-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 May 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012877.pub2">https://doi.org/10.1002/14651858.CD012877.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012877-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012877-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012877-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012877-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012877-abs-0006">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012877-abs-0001" lang="en"> <section id="CD012877-sec-0001"> <h3 class="title" id="CD012877-sec-0001">Background</h3> <p>Conventional medications for Crohn's disease (CD) include anti‐inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first‐line treatments, then biologic therapies such as tumour necrosis factor‐alpha (TNF‐α) antagonists such as adalimumab are considered for treating CD. Maintenance of remission of CD is a clinically important goal, as disease relapse can negatively affect quality of life. </p> </section> <section id="CD012877-sec-0002"> <h3 class="title" id="CD012877-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of adalimumab for maintenance of remission in people with quiescent CD. </p> </section> <section id="CD012877-sec-0003"> <h3 class="title" id="CD012877-sec-0003">Search methods</h3> <p>We searched the Cochrane IBD Group Specialized Register, CENTRAL, MEDLINE, Embase, and clinicaltrials.gov from inception to April 2019. </p> </section> <section id="CD012877-sec-0004"> <h3 class="title" id="CD012877-sec-0004">Selection criteria</h3> <p>We considered for inclusion randomized controlled trials (RCTs) comparing adalimumab to placebo or to an active comparator. </p> </section> <section id="CD012877-sec-0005"> <h3 class="title" id="CD012877-sec-0005">Data collection and analysis</h3> <p>We analyzed data on an intention‐to‐treat basis. We calculated risk ratios (RRs) and corresponding 95% confidence intervals (95% CI) for dichotomous outcomes. The primary outcome was failure to maintain clinical remission. We define clinical remission as a Crohn's Disease Activity Index (CDAI) score of &lt; 150. Secondary outcomes were failure to maintain clinical response, endoscopic remission, endoscopic response, histological remission and adverse events (AEs). We assessed biases using the Cochrane 'Risk of bias' tool. We used GRADE to assess the overall certainty of evidence supporting the primary outcome. </p> </section> <section id="CD012877-sec-0006"> <h3 class="title" id="CD012877-sec-0006">Main results</h3> <p>We included six RCTs (1158 participants). We rated four trials at low risk of bias and two trials at unclear risk of bias. All participants had moderate‐to‐severe CD that was in clinical remission. Four studies were placebo‐controlled (1012 participants). Two studies (70 participants) compared adalimumab to active medication (azathioprine, mesalamine or 6‐mercaptopurine) in participants who had an ileocolic resection prior to study enrolment. </p> <p><b>Adalimumab versus placebo</b><br/>Fifty‐nine per cent (252/430) of participants treated with adalimumab failed to maintain clinical remission at 52 to 56 weeks, compared with 86% (217/253) of participants receiving placebo (RR 0.70, 95% CI 0.64 to 0.77; 3 studies, 683 participants; high‐certainty evidence). Among those who received prior TNF‐α antagonist therapy, 69% (129/186) of adalimumab participants failed to maintain clinical or endoscopic response at 52 to 56 weeks, compared with 93% (108/116) of participants who received placebo (RR 0.76, 95% CI 0.68 to 0.85; 2 studies, 302 participants; moderate‐certainty evidence). Fifty‐one per cent (192/374) of participants who received adalimumab failed to maintain clinical remission at 24 to 26 weeks, compared with 79% (149/188) of those who received placebo (RR 0.66, 95% CI 0.52 to 0.83; 2 studies, 554 participants; moderate‐certainty evidence). Eighty‐seven per cent (561/643) of participants who received adalimumab reported an AE compared with 85% (315/369) of participants who received placebo (RR 1.01, 95% CI 0.94 to 1.09; 4 studies, 1012 participants; high‐certainty evidence). Serious adverse events were seen in 8% (52/643) of participants who received adalimumab and 14% (53/369) of participants who received placebo (RR 0.56, 95% CI 0.39 to 0.80; 4 studies, 1012 participants; moderate‐certainty evidence) and withdrawal due to AEs was reported in 7% (45/643) of adalimumab participants compared to 13% (48/369) of placebo participants (RR 0.59, 95% CI 0.38 to 0.91; 4 studies, 1012 participants; moderate‐certainty evidence). Commonly‐reported AEs included CD aggravation, arthralgia, nasopharyngitis, urinary tract infections, headache, nausea, fatigue and abdominal pain. </p> <p><b>Adalimumab versus active comparators</b> </p> <p>No studies reported failure to maintain clinical remission. One study reported on failure to maintain clinical response and endoscopic remission at 104 weeks in ileocolic resection participants who received either adalimumab, azathioprine or mesalamine as post‐surgical maintenance therapy. Thirteen per cent (2/16) of adalimumab participants failed to maintain clinical response compared with 54% (19/35) of azathioprine or mesalamine participants (RR 0.23, 95% CI 0.06 to 0.87; 51 participants). Six per cent (1/16) of participants who received adalimumab failed to maintain endoscopic remission, compared with 57% (20/35) of participants who received azathioprine or mesalamine (RR 0.11, 95% CI 0.02 to 0.75; 51 participants; very low‐certainty evidence). One study reported on failure to maintain endoscopic response at 24 weeks in ileocolic resection participants who received either adalimumab or 6‐mercaptopurine (6‐MP) as post‐surgical maintenance therapy. Nine per cent (1/11) of adalimumab participants failed to maintain endoscopic remission compared with 50% (4/8) of 6‐MP participants (RR 0.18, 95% CI 0.02 to 1.33; 19 participants). </p> </section> <section id="CD012877-sec-0007"> <h3 class="title" id="CD012877-sec-0007">Authors' conclusions</h3> <p>Adalimumab is an effective therapy for maintenance of clinical remission in people with quiescent CD. Adalimumab is also effective in those who have previously been treated with TNF‐α antagonists. The effect of adalimumab in the post‐surgical setting is uncertain. More research is needed in people with recent bowel surgery for CD to better determine treatment plans following surgery. Future research should continue to explore factors that influence initial and subsequent biologic selection for people with moderate‐to‐severe CD. Studies comparing adalimumab to other active medications are needed, to help determine the optimal maintenance therapy for CD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012877-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012877-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012877-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012877-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012877-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012877-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012877-abs-0008">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012877-abs-0002" lang="en"> <h3>Adalimumab for maintenance of remission in Crohn's disease</h3> <p><b>What is Crohn's disease?</b> </p> <p>Crohn's disease (CD) is an inflammatory disorder that can affect the whole gastrointestinal tract from the mouth to the anus. Participants can experience a wide range of symptoms related to their disease, including abdominal pain, diarrhea, weight loss, and fever. Participants commonly have periods where their disease is more active (in other words, they experience symptoms), alternating with periods where their disease is inactive (no CD symptoms). When CD is inactive it is said to be in remission. With treatment, medications can control the inflammation in the gastrointestinal tract, for long‐term control of disease activity. </p> <p><b>What is adalimumab?</b> </p> <p>Adalimumab is a biologic drug that blocks the development of inflammation in the gastrointestinal tract. It belongs to a class of drugs know as tumour necrosis factor‐alpha (TNF‐α) antagonists. This medication is used in people who have CD, to reduce the amount of inflammation in the gastrointestinal tract or to prevent the inflammation from developing. </p> <p><b>What is the purpose of this study?</b> </p> <p>The purpose of this study was to determine whether adalimumab is an effective medication for maintenance of remission in people with inactive CD, and whether it is associated with any harms or side effects. </p> <p><b>How was this study performed?</b> </p> <p>We conducted a systematic review of current literature, to determine whether adalimumab therapy is effective in maintaining remission in CD. We ran electronic searches of several databases on 15 April 2019 and selected studies that met our inclusion criteria for further evaluation. We performed statistical analyses to determine whether adalimumab provides an overall benefit for maintenance of remission in CD. </p> <p><b>What were the results?</b> </p> <p>We included six studies (1158 participants). All participants had moderate‐to‐severe CD that was in clinical remission. Four studies (1012 participants) compared adalimumab to placebo (a fake drug). Two studies (70 participants) compared adalimumab to active medication (azathioprine or mesalamine and 6‐mercaptopurine) in participants who had surgery for CD before study enrolment. </p> <p>Participants who received adalimumab were more likely to maintain clinical remission (no symptoms of CD) and endoscopic remission (no inflammation in their gastrointestinal tract) than those who received placebo (the fake drug). This was also true for participants who have previously been treated with other TNF‐α drugs (for example, infliximab), The overall certainty of the evidence for these outcomes ranged from moderate to high. We did not see an increased rate of side effects in participants who received adalimumab compared to those who received placebo. The most common side effects included headache, fatigue and infections, both urinary tract infections and upper respiratory tract infections. </p> <p>Two small studies looked at groups of patients who had recently required a narrowed area of their bowel to be removed by surgery. These participants were given adalimumab or azathioprine (an immunosuppressive drug), mesalamine (an anti‐inflammatory drug), or 6‐mercaptopurine (an immunosuppressive drug) within 45 days of surgery, to see if these drugs helped to prolong remission after surgery. Overall, adalimumab appeared to be more likely to maintain remission than azathioprine, mesalamine or 6‐mercaptopurine. Howvever, these were small studies with very low‐certainty evidence. These two studies did not report on side effects. </p> <p><b>What are the conclusions from this study?</b> </p> <p>Adalimumab is an effective therapy for maintaining clinical remission in people with inactive CD. Adalimumab is also effective in those who have previously been treated with other TNF‐α drugs. The effect of adalimumab in the post‐surgical setting is uncertain. More research is needed in patients following bowel surgery for CD to better determine treatment plans after their operations. Future research should continue to explore factors that influence initial and later biologic selection for participants with moderate‐to‐severe CD. Studies comparing adalimumab to other active medications are needed, to help decide the best maintenance therapy for CD. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012877-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012877-sec-0073"></div> <h3 class="title" id="CD012877-sec-0074">Implications for practice</h3> <section id="CD012877-sec-0074"> <p>Adalimumab is an effective therapy to maintain clinical remission in participants with CD. Adalimumab is also effective in participants who have previously been treated with TNF‐α antagonists. The effect of adalimumab in the post‐surgical setting is uncertain. </p> </section> <h3 class="title" id="CD012877-sec-0075">Implications for research</h3> <section id="CD012877-sec-0075"> <p>More high‐quality well‐powered studies are needed in this area. More research is needed in participants with recent bowel surgery for CD, to better determine treatment plans following surgery. Future research should continue to explore factors that influence initial and subsequent biologic selection for participants with moderate‐to‐severe CD. Studies comparing adalimumab to other active medications are needed, to help determine the optimal maintenance therapy for CD. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012877-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012877-sec-0008"></div> <div class="table" id="CD012877-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Adalimumab compared to placebo for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab compared to placebo for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with quiescent Crohn's disease<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> Adalimumab (40 mg/week or 40 mg every other week)<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Adalimumab</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain clinical remission</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.64 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>683<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission defined as a CDAI &lt; 150</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>858 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000<br/>(549 to 660) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain clinical remission</p> <p>Follow‐up: 24 to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.52 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>554<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission defined as a CDAI &lt; 150</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>793 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>523 per 1000<br/>(412 to 658) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to maintain endoscopic remission</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>969 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>717 per 1000</p> <p>(611 to 843)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.74</p> <p>(0.63 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic remission defined as an absence of mucosal ulceration</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1012<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Commonly‐reported adverse events included CD aggravation, arthralgia, nasopharyngitis, urinary tract infections, headache, nausea, fatigue and abdominal pain </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>854 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>862 per 1000<br/>(802 to 930) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/>(0.39 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1012<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported serious adverse events included infectious complications including tuberculosis, abscess formation and wound infections, multiple sclerosis, pulmonary embolism </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/>(56 to 115) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawals due to adverse events</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.38 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1012<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal included flare of CD, infectious complications</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000<br/>(49 to 118) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/>(0.68 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>302<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response defined as decrease in baseline CDAI score of ≥ 100. Endoscopic response defined as mucosal healing seen at time of endoscopy </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>708 per 1000<br/>(633 to 791) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious inconsistency (I<sup>2</sup> = 55%).<br/><sup>b</sup>Downgraded by one level due to sparse data (109 events).<br/><sup>c</sup>Downgraded by one level due to sparse data (105 events).<br/><sup>d</sup>Downgraded by one level due to sparse data (93 events).<br/><sup>e</sup>Downgraded by one level due to sparse data (237 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012877-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Adalimumab compared to active comparator for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab compared to active comparator for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with quiescent Crohn's disease (ileocolic resection)<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> Adalimumab (40 mg every other week)<br/><b>Comparison:</b> Active comparator ‐ azathioprine (2 mg/kg/day), mesalamine (3 g/day), or 6‐mercaptopurine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with active comparator</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Adalimumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure to maintain clinical remission</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain endoscopic remission</p> <p>Follow‐up: 104 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.11<br/>(0.02 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic remission defined as Rutgeerts score &lt; i2</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/>(11 to 429) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to unclear risk of bias.<br/><sup>b</sup>Downgraded two levels due to very sparse data (21 events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012877-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012877-sec-0009"></div> <section id="CD012877-sec-0010"> <h3 class="title" id="CD012877-sec-0010">Description of the condition</h3> <p>Crohn's disease (CD) is a chronic, episodic, inflammatory condition of the gastrointestinal system, with affected regions consisting of transmural ulceration separated by normal mucosa. The small intestine is most commonly affected, although the large intestine may also be involved. Common symptoms include abdominal pain, diarrhea, weight loss, bleeding, nausea and vomiting. Enteric complications may include bowel obstruction, perforation, abscesses, fistulas, and peri‐anal disease. Approximately 20% of people with CD experience extra‐intestinal complications that may include musculoskeletal, ocular, dermatologic, hepatobiliary, renal and hematological conditions (<a href="./references#CD012877-bbs2-0019" title="DohertyGM . Current Diagnosis &amp; Treatment. McGraw-Hill Education LLC, 2015.">Doherty 2015</a>). </p> <p>The pathophysiology of CD is complex and not completely understood. However, it is known that there is a genetic component, as evidenced by concordance between monozygotic twins, familial and ethnic aggregation, and genetic anticipation (<a href="./references#CD012877-bbs2-0027" title="KhorB , GardetA , XavierR . Genetics and pathogenesis of inflammatory bowel disease. Nature2011;474(7351):307-17.">Khor 2011</a>; <a href="./references#CD012877-bbs2-0028" title="LoddoI , RomanoC . Inflammatory bowel disease: genetics, epigenetics and pathogenesis. Frontiers in Immunology2015;6:1-6.">Loddo 2015</a>). Evidence also exists for strong epigenetic and environmental factors, with tobacco use being the most studied environmental factor, showing that early tobacco use increases the risk of developing CD (<a href="./references#CD012877-bbs2-0017" title="CosnesJ , CarbonnelF , BeaugerieL , QuintrecYL , GendreJ . Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology1996;110(2):424-31.">Cosnes 1996</a>; <a href="./references#CD012877-bbs2-0027" title="KhorB , GardetA , XavierR . Genetics and pathogenesis of inflammatory bowel disease. Nature2011;474(7351):307-17.">Khor 2011</a>). The disease is known to occur after an episode of infectious gastroenteritis, suggesting that an altered gut microbiota may be a factor in the pathogenesis of CD (<a href="./references#CD012877-bbs2-0016" title="ChassaingB , Darfeuille–MichaudA . The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology2011;140(6):1720-8.">Chassaing 2011</a>; <a href="./references#CD012877-bbs2-0029" title="MatsuokaK , KanaiT . The gut microbiota and inflammatory bowel disease. Seminars in Immunopathology2015;37(1):47-55.">Matsuoka 2015</a>). It is believed that an altered relationship between the gut microflora and the host immune system plays a major role in CD. One key potential mechanism by which this altered relationship is thought to mediate the development of CD is through increased permeability between epithelial cells lining the intestinal barrier. The increased permeability permits an increased flux of intestinal antigens to the lamina propria, causing an enhanced immune reaction. In‐vitro and animal studies have linked the increase in permeability to T cells, tumour necrosis factor‐alpha (TNF‐α), and interferon‐γ (<a href="./references#CD012877-bbs2-0014" title="BaumgartDC , SandbornWJ . Crohn's disease. Lancet2012;380(9853):1590-605.">Baumgart 2012</a>). </p> <p>Conventional medications for CD include anti‐inflammatory drugs, immunosuppressants and corticosteroids. However, if the patient does not respond, or loses response to these first‐line treatments, then biologic therapies such as TNF‐α antagonists including infliximab, certolizumab pegol and adalimumab are then considered for the treatment of CD. Top‐down approaches for CD therapy, including the early use of combination therapy with biologics and immunosuppressives, are increasingly being used and may provide benefit in people with complicated or extensive disease suggestive of an aggressive disease course, and those with poor prognostic factors (<a href="./references#CD012877-bbs2-0036" title="TsuiJJ , HuynhHQ . Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?Annals of Gastroenterology2018;31(4):413-24.">Tsui 2018</a>). </p> </section> <section id="CD012877-sec-0011"> <h3 class="title" id="CD012877-sec-0011">Description of the intervention</h3> <p>Adalimumab is a monoclonal antibody that binds to and inactivates TNF‐α, thereby limiting the inflammatory response that occurs in CD. Since its initial approval by the FDA for treatment of rheumatoid arthritis, adalimumab has been approved for several other diseases, including hidradenitis suppurativa, iritis, ankylosing, psoriatic, and juvenile idiopathic arthritis; plaque psoriasis; ulcerative colitis; and CD (<a href="./references#CD012877-bbs2-0021" title="FDA. HUMIRA: Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf (accessed 15 June 2017).">FDA 2011</a>). Adalimumab is indicated for cases of moderate‐to‐severe CD for symptomatic control and induction and maintenance of clinical remission (<a href="./references#CD012877-bbs2-0015" title="CassinottiA , ArdizzoneS , PorroGB . Adalimumab for the treatment of Crohn's disease. Biologics2008;2(4):763-77.">Cassinotti 2008</a>). </p> </section> <section id="CD012877-sec-0012"> <h3 class="title" id="CD012877-sec-0012">How the intervention might work</h3> <p>It has been demonstrated that people with CD have higher concentrations of TNF‐α and decreased immune cell apoptosis in their intestinal mucosa (<a href="./references#CD012877-bbs2-0018" title="Di SabatinoA , CiccocioppoR , CinqueB , MillimaggiD , MoreraR , RicevutiL , et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut2004;53(1):70-7.">Di Sabatino 2004</a>). Inhibition of TNF‐α by adalimumab reduces activity of neutrophils, proliferation of T‐cells, activation of macrophages, and survival of immune cells, thereby limiting the immune response (<a href="./references#CD012877-bbs2-0035" title="TraceyD , KlareskogL , SassoEH , SalfeldJG , TakPP . Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology Therapy2008;117(2):244-79.">Tracey 2008</a>). In addition, TNF‐α inhibition has been shown to increase intestinal T‐cell and monocyte apoptosis in people with CD (<a href="./references#CD012877-bbs2-0012" title="AsgharpourA , ChengJ , BickstonS . Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clinical and Experimental Gastroenterology2013;6(6):153-60.">Asgharpour 2013</a>). </p> </section> <section id="CD012877-sec-0013"> <h3 class="title" id="CD012877-sec-0013">Why it is important to do this review</h3> <p>Maintenance of remission of CD is a clinically important goal, as relapses of the disease can have a profound impact on the quality of life of patients (<a href="./references#CD012877-bbs2-0022" title="GhoshS , MitchellR . Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. Journal of Crohn's &amp; Colitis2007;1(1):10-20.">Ghosh 2007</a>). Commonly‐used treatment options for active CD include corticosteroids, which are effective for short‐term disease control, but are associated with several adverse events (AEs). Furthermore, corticosteroid resistance occurs in as many as 20% of cases (<a href="./references#CD012877-bbs2-0031" title="MunkholmP , LangholzE , DavidsenM , BinderV . Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut1994;35(3):360-2.">Munkholm 1994</a>; <a href="./references#CD012877-bbs2-0034" title="SteinhartAH , EweK , GriffithsAM , ModiglianiR , ThomsenOO . Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD000301]">Steinhart 2003</a>). Corticosteroids are not effective for maintenance of remission in CD (<a href="./references#CD012877-bbs2-0034" title="SteinhartAH , EweK , GriffithsAM , ModiglianiR , ThomsenOO . Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD000301]">Steinhart 2003</a>). Furthermore, many patients do not respond to treatment with aminosalicylates and immunosuppressives (<a href="./references#CD012877-bbs2-0024" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9.">Hanauer 2002</a>). </p> <p>Adalimumab is a promising option for the treatment of moderate‐to‐severe CD. The CHARM trial showed that adalimumab is more effective than placebo in maintaining remission in moderate‐to‐severe CD after 56 weeks from initiation of therapy (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>). Unfortunately, the human immune system may reduce the effectiveness of interventions over time, and the effectiveness of a monoclonal antibody for initial remission of CD may not predict its ability to maintain remission. For example, it has been shown that repeated infusions of infliximab, a chimeric monoclonal antibody to TNF‐α used to treat CD, may lead to the production of antibodies to the drug itself, thereby reducing its ability to maintain remission (<a href="./references#CD012877-bbs2-0013" title="BaertF , NomanM , VermeireS , Van AsscheG , D’HaensG , CarbonezA , et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. New England Journal of Medicine2003;348(7):601-8.">Baert 2003</a>). The development of anti‐drug antibodies with adalimumab treatment has also been reported and may have implications for long‐term treatment (<a href="./references#CD012877-bbs2-0030" title="MosesJ , Lambert-JenkinsK , MomotazH , SattarA , DebanneSM , SplawskiJ , et al. Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy. European Journal of Gastroenterology &amp; Hepatology2019;31(10):1228-33.">Moses 2019</a>). It is therefore necessary to conduct a review to determine the efficacy and safety of adalimumab for maintenance of remission in CD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012877-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012877-sec-0014"></div> <p>To assess the efficacy and safety of adalimumab for maintenance of remission in people with quiescent CD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012877-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012877-sec-0015"></div> <section id="CD012877-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012877-sec-0017"> <h4 class="title">Types of studies</h4> <p>We include randomized controlled trials (RCTs) that assessed the efficacy and safety of adalimumab for maintenance of remission in CD. </p> </section> <section id="CD012877-sec-0018"> <h4 class="title">Types of participants</h4> <p>This review includes participants of any age who have been diagnosed with CD using clinical, radiological, endoscopic or histological criteria. Participants must be in remission (as defined by the included studies) at study entry to be included. </p> </section> <section id="CD012877-sec-0019"> <h4 class="title">Types of interventions</h4> <p>This review includes trials that compared adalimumab either to a placebo or to an active comparator. </p> </section> <section id="CD012877-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012877-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The proportion of participants with CD who failed to maintain clinical remission, as defined by the original trials. Clinical remission is often defined as a Crohn's Disease Activity Index (CDAI) score of &lt; 150. </p> </section> <section id="CD012877-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>The proportion of participants:</p> <p> <ol id="CD012877-list-0001"> <li> <p>Who failed to maintain clinical response;</p> </li> <li> <p>Who failed to maintain endoscopic remission;</p> </li> <li> <p>Who failed to maintain endoscopic response;</p> </li> <li> <p>Who failed to maintain clinical or endoscopic response with prior TNF‐α exposure;</p> </li> <li> <p>Who failed to maintain histologic remission;</p> </li> <li> <p>Who failed to maintain histologic response;</p> </li> <li> <p>Who failed to maintain steroid withdrawal;</p> </li> <li> <p>Who developed adverse events (AEs);</p> </li> <li> <p>Who developed serious adverse events (SAEs);</p> </li> <li> <p>Who withdrew due to AEs; and</p> </li> <li> <p>Quality of life.</p> </li> </ol> </p> </section> </section> </section> <section id="CD012877-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012877-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for relevant studies from inception to 15 April 2019: </p> <p> <ol id="CD012877-list-0002"> <li> <p>Cochrane IBD Group Specialized Register;</p> </li> <li> <p>Cochrane Central Register of Controlled trials (CENTRAL);</p> </li> <li> <p>MEDLINE (Ovid);</p> </li> <li> <p>Embase (Ovid).</p> </li> </ol> </p> <p>The search strategies are listed in <a href="./appendices#CD012877-sec-0078">Appendix 1</a>. </p> </section> <section id="CD012877-sec-0025"> <h4 class="title">Searching other resources</h4> <p>As well as searching the electronic databases, we identified additional studies by handsearching the reference lists of relevant papers. We conducted handsearches of conference proceedings from Digestive Disease Week, United European Gastroenterology Week and the European Crohn's and Colitis Organisation Congress for the last five years. We identified ongoing trials by approaching leading experts in the field, and by searching the <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> database and <a href="http://controlled-trials.com" target="_blank">controlled-trials.com</a> databases. </p> </section> </section> <section id="CD012877-sec-0026"> <h3 class="title" id="CD012877-sec-0026">Data collection and analysis</h3> <section id="CD012877-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CT and TN) independently assessed the titles and abstracts of studies identified by the search criteria to determine eligibility according to the inclusion criteria. We discussed disagreements until we reached a consensus among the review authors, and consulted with a third review author (JKM) when we could not reach agreement. </p> </section> <section id="CD012877-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CT and TN) independently extracted data using a standardized extraction form. We discussed any disagreements over extracted data, and then brought them to a third review author (JKM) for resolution as required. We extracted the following information: </p> <p> <ol id="CD012877-list-0003"> <li> <p>General information (type of publication, title, journal, year);</p> </li> <li> <p>Study design features (method of randomization, concealment of allocation and blinding, power calculation, a priori and post hoc analyses, dates of enrolment and follow‐up, study duration, number of centres and location, and study withdrawals); </p> </li> <li> <p>Eligibility (number of participants screened and their randomization);</p> </li> <li> <p>Participant characteristics (age, sex, race, severity of disease, current and prior medications); </p> </li> <li> <p>Intervention (dose and type of medication, and whether it was compared to placebo or active comparator); </p> </li> <li> <p>Primary and secondary outcomes;</p> </li> <li> <p>Follow‐up (dates of follow‐up along with withdrawals and number of participants lost to follow‐up); </p> </li> <li> <p>Funding details and author conflicts of interest.</p> </li> </ol> </p> </section> <section id="CD012877-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CT and TN) independently assessed risks of bias using the Cochrane 'Risk of bias' tool (<a href="./references#CD012877-bbs2-0026" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We assessed several study characteristics for risks of bias, including random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias. Based on these criteria, we rated the studies as having a low, high or unclear risk of bias for each category. We discussed any disagreements about risks of bias and then brought them to a third review author (JKM) as necessary. </p> </section> <section id="CD012877-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5 (RevMan5) to analyze the data. For dichotomous outcomes, we calculated the risk ratio (RR) with a 95% confidence interval (CI). For continuous outcomes, we calculated the mean difference (MD) with a 95% CI. </p> </section> <section id="CD012877-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>To ensure independent comparisons between each treatment group (e.g. dose groups) and placebo, we divided the placebo group across the number of treatment groups to deal with trials with multiple arms. For trials with an odd number of participants in the placebo group, we split the placebo group so that the placebo group for the lower‐dose arm had a larger number of participants. This helped avoid overestimating treatment effects for the higher‐dose arm. We included cross‐over trials if the data prior to the first cross‐over were available. We reported on the proportion of participants who experienced at least one event, for studies where events may recur (e.g. AEs). </p> </section> <section id="CD012877-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to obtain missing data when necessary. According to the intention‐to‐treat (ITT) analysis, we assumed that participants with missing dichotomous outcome data were treatment failures. We performed a sensitivity analysis to determine the impact of the assumption of treatment failure for missing data on the effect estimate. We conducted an available‐case analysis in the event of missing continuous outcome data. </p> </section> <section id="CD012877-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD012877-bbs2-0025" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We considered an I<sup>2</sup> value of less than 25% indicative of low heterogeneity, greater than 50% indicative of moderate heterogeneity and greater than 75% high heterogeneity. For the Chi<sup>2</sup> test, we considered a P value of 0.10 to be statistically significant. If the I<sup>2</sup> statistic and Chi<sup>2</sup> test suggested heterogeneity, we visually inspected the forest plot for outliers. We used a sensitivity analysis (e.g. excluding outliers) to explore potential explanations for heterogeneity. </p> </section> <section id="CD012877-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We evaluated reporting bias by comparing outcomes listed in protocols (or in the Methods section of the published paper if no protocol is available) to those reported in the final article. If a sufficient number of studies were included (more than 10) in the pooled analysis, we planned to use a funnel plot to assess publication bias (<a href="./references#CD012877-bbs2-0020" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). As this review only includes six studies, we did not construct a funnel plot. </p> </section> <section id="CD012877-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We combined data from individual trials for meta‐analysis when interventions, participant groups and outcomes were sufficiently similar. We determined this by discussion and consensus among the review author team. We calculated the pooled RR with a 95% CI for dichotomous outcomes, and the pooled MDs with a 95% CI for continuous outcomes that were measured with the same scale. When different scales were used to measure the same underlying construct (e.g. quality of life), we calculated the standardized mean difference (SMD) with its 95% CI. We used a random‐effects model to pool the data. If we detected a high degree of heterogeneity (I<sup>2</sup> &gt; 75%), we did not pool data for meta‐analysis. </p> </section> <section id="CD012877-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned for the following subgroup analyses:</p> <p> <ol id="CD012877-list-0004"> <li> <p>Participant characteristics (disease duration, disease severity, disease extent, concomitant medication); and </p> </li> <li> <p>Drug doses and routes of administration.</p> </li> </ol> </p> <p>The data only allowed for a subgroup analysis by drug dose regimen.</p> </section> <section id="CD012877-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We used sensitivity analysis to examine the impact of the following variables on the pooled effect estimate: </p> <p> <ol id="CD012877-list-0005"> <li> <p>Random‐effects versus fixed‐effect modeling;</p> </li> <li> <p>Low risk of bias versus unclear or high risk of bias;</p> </li> <li> <p>Relevant loss to follow‐up (more than 10%): best‐case versus worst‐case scenario; and </p> </li> <li> <p>Full‐text articles versus abstract or unpublished studies.</p> </li> </ol> </p> </section> <section id="CD012877-sec-0038"> <h4 class="title">Summary of Findings Table</h4> <p>We used GRADE to assess the overall certainty of the evidence supporting the primary and secondary outcomes (<a href="./references#CD012877-bbs2-0032" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al, on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>). For the 'Summary of findings' table, we included the following outcomes: failure to maintain clinical remission (at study endpoint), failure to maintain endoscopic remission, adverse events, serious adverse events, withdrawals due to adverse events, and failure to maintain clinical or endoscopic response in patients with previous TNF‐α exposure. </p> <p>RCTs begin as high‐certainty evidence, and may be downgraded according to:</p> <p> <ol id="CD012877-list-0006"> <li> <p>Risk of bias;</p> </li> <li> <p>Indirect evidence;</p> </li> <li> <p>Inconsistency (unexplained heterogeneity);</p> </li> <li> <p>Imprecision (sparse data); and</p> </li> <li> <p>Reporting bias (publication bias).</p> </li> </ol> </p> <p>After considering each of these elements, we classified the overall quality of the evidence supporting each outcome as high‐certainty (further research is very unlikely to change our confidence in the estimate of effect); moderate‐certainty (further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low‐certainty (further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); or very low‐certainty (we are very uncertain about the estimate) (<a href="./references#CD012877-bbs2-0023" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012877-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012877-sec-0039"></div> <section id="CD012877-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD012877-sec-0041"> <h4 class="title">Results of the search</h4> <p>A literature search conducted on 15 April 2019 identified 1766 records. After we had removed duplicates 1298 records were left for review. Two review authors (CT and TN) independently reviewed the titles and abstracts of these records and selected 40 full‐text articles for review (see <a href="#CD012877-fig-0001">Figure 1</a>). We excluded four studies with reasons (see <a href="./references#CD012877-sec-0085" title="">Characteristics of excluded studies</a>). Thirty‐seven reports of six studies (total of 1158 participants) met the predefined inclusion criteria and were included in this review (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Four of these studies were randomized placebo‐controlled trials (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>) and two were active‐comparator trials (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; see <a href="./references#CD012877-sec-0084" title="">Characteristics of included studies</a>). We found one ongoing study, but with no available data (<a href="./references#CD012877-bbs2-0011" title="NCT03464136. Safety and efficacy of adalimumab versus ustekinumab for one year (SEAVUE). clinicaltrials.gov/ct2/show/NCT03464136 (first received 13 March 2018). ">NCT03464136</a>). </p> <div class="figure" id="CD012877-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012877-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012877-sec-0042"> <h4 class="title">Included studies</h4> <p><a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>, the CHARM trial, was a randomized, double‐blind, placebo‐controlled trial. In this study, 499 adult participants with known moderate‐to‐severe CD (CDAI 220 to 450) diagnosed either endoscopically or radiologically were considered for inclusion. Participants had to be on stable doses of azathioprine, 6‐mercapropurine, methotrexate, 5‐aminosalicylates, sulfsalazine, or oral mesalamine for at least four weeks prior to screening. CD‐related antibiotics were permitted if at stable doses for two weeks prior to screening. Prednisone (≤ 30 mg of prednisone a day) or budesonide (≤ 9 mg daily) were permitted if participants were taking a stable dose for at least two weeks before screening. Participants could have been on TNF‐α antagonists other than adalimumab previously, provided it was more than 12 weeks prior to randomization and they did not have a clinical response to the medication. </p> <p>Exclusion criteria included symptomatic obstructive disease, bowel resection within six months prior to screening, an ostomy, extensive small bowel resection or short bowel syndrome, current total parenteral nutrition (TPN) therapy, previous history of cancer, HIV, demyelinating diseases, <i>Listeria</i> infection, positive <i>Clostridium difficile</i> assay, untreated tuberculosis, previous chemotherapy within 30 days prior to screening, or poorly‐controlled comorbid conditions. Women who were currently pregnant or breastfeeding were excluded. People who had a history of illicit drug use or a significant alcohol history within the last year were also excluded. Individuals were also excluded if they had previously been given adalimumab, a rectal enema two weeks prior to screening or received cyclosporine, mycophenolate mofetil or tacrolimus eight weeks prior to screening. </p> <p>Participants initially entered a two‐week screening period where they received open‐label adalimumab 80 mg subcutaneously at week 0 and 40 mg at week 2. Participants were randomized at week 4 to one of three groups: adalimumab 40 mg every other week (eow); adalimumab 40 mg weekly; or placebo, and were also stratified by responder status (decrease in CDAI ≥ 70) and previous TNF‐α antagonist exposure. Participants who flared during the study timeline were moved to an open‐label study. Primary end points included the participants who responded at week 4, defined as a decrease in CDAI ≥ 70, and participants who achieved clinical remission, defined as CDAI &lt; 150 at weeks 26 and 56. </p> <p>Secondary end points included the number of participants with a clinical response (decrease in CDAI score from baseline by ≥ 70 points and by ≥ 100 points) at weeks 26 and 56; changes from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total scores at weeks 26 and 56; number of participants in clinical remission at weeks 26 and 56 who were able to discontinue corticosteroid use; number of participants in clinical remission at weeks 26 and 56 who were able to discontinue corticosteroid use for ≥ 90 days; number of participants with fistula remission (closure of all fistulas); number of participants using immunosuppressants; prior TNF‐α antagonist use (experienced versus naïve); median time in clinical remission among randomized responders achieving remission; and AEs. </p> <p><a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>, the EXTEND trial, was a randomized placebo‐controlled trial including 129 adult participants. Participants were included in this trial if they had moderate‐to‐severe CD (CDAI 220 to 450) and active mucosal ulceration during screening ileocolonoscopy. Therapy with azathioprine, 6‐mercaptopurine, and methotrexate was allowed, if participants were taking these medications for at least 12 weeks and at a stable dose for at least four weeks prior to screening. Participants could remain on prescribed aminosalicylates or CD‐related antibiotics, if they were on a stable dose for at least four weeks prior to screening. Participants who had previously received infliximab or other TNF‐α antagonists, excluding adalimumab, were eligible unless they had no clinical response. Treatment with prednisone (maximum dose 40 mg/day) or budesonide (maximum dose 9 mg/day) was allowed if participants were taking a stable dose for at least two weeks before screening. Exclusion criteria included TNF‐α antagonist exposure within eight weeks of screening, use of any other study medication during the study, and prior exposure to adalimumab or natalizumab. </p> <p>Participants initially received an open‐label induction of adalimumab, 160 mg subcutaneously at week 0 and 80 mg at week 4. Participants were randomized to adalimumab 40 mg eow or placebo. Participants who flared during the study timeline were moved to an open‐label study. </p> <p>The primary end point was mucosal healing at week 12. Secondary end points included mucosal healing at week 52, the Crohn's Disease Endoscopic Index of Severity (CDEIS) score at weeks 12 and 52, CDAI remission and response, and AEs. </p> <p>Reinisch et al. reported additional data from the EXTEND study, i.e. 199 adult participants with moderate‐to‐severe CD (CDAI 220 to 450) who had active mucosal ulceration during screening ileocolonoscopy were considered for inclusion. Study design is previously described under <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>. Study end points included CDEIS score at weeks 12 and 52, Simple Endoscopic Score for CD (SES‐CD) score at weeks 12 and 52, and mucosal healing at week 12. </p> <p>In <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>, the CLASSIC II trial, 55 participants with moderate‐to‐severe CD (CDAI 220 to 450) who were in clinical remission at the end of the CLASSIC I trial were considered for inclusion. All patients deemed to have normal cardiac, renal and hepatic function were considered for inclusion. Prior to randomization, participants were given adalimumab 40 mg at week 0 and 40 mg at week 2. Participants who were in clinical remission (CDAI &lt; 150) at week 4 were randomized to one of three groups in a 1:1:1 ratio: adalimumab 40 mg eow; adalimumab 40 mg weekly; and placebo. Participants were followed to week 56. Participants who experienced a flare of their disease during the study timeline could be moved to the open‐label study. All other medications were kept at stable doses throughout the trial, except that prednisone doses greater than 10 mg were tapered by 5 mg starting at week 8 until participants were on 10 mg/kg a day and then the dose was reduced by 2.5 mg a week until stopped. </p> <p>The primary end point was the number of participants in clinical remission (CDAI &lt; 150) at week 56. Secondary outcomes included the number of participants in clinical remission (CDAI &lt; 150) at week 24; 100‐point clinical response (decrease in CDAI ≥ 100) at weeks 24 and 56; 70‐point clinical response (decrease in CDAI ≥ 70) at weeks 24 and 56; IBDQ score; number of participants who stopped steroid therapy without loss of remission at weeks 24 and 56; and AEs. However, authors acknowledged that the study was not adequately powered for the primary end point. </p> <p>In <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>, 50 patents aged 15 to 75 with moderate‐to‐severe ileocolonic CD (CDAI 220 to 450) diagnosed at least four months prior to study enrolment were considered for inclusion. Participants were allowed prior exposure to TNF‐α antagonists other than adalimumab, providing it was not within eight weeks of study enrolment. Exclusion criteria included no response to prior TNF‐α antagonist, a history of cancer, hematologic malignancy or lymphoproliferative disorder, active or latent tuberculosis infection, active HIV infection, active <i>Clostridium difficile</i> infection, infections requiring hospital admission, intravenous antibiotics in the last 28 days or oral antibiotics in the last 14 days, history of demyelinating disease, bowel resection within the last six months, body weight less than 30 kg, receiving TPN or enteral nutrition, abnormalities on electrocardiogram, uncontrolled comorbid condition putting them at risk by participating in the trial, and women of child‐bearing age who were not on an effective form of birth control. </p> <p>Participants initially entered an induction trial where they were randomized to one of three groups in a 2:3:3 ratio: placebo; adalimumab 160 mg at week 0 and 80 mg at week 2; or adalimumab 80 mg at week 0 and 40 mg at week 2. Participants were eligible for enrolment in the maintenance trial if they had at least a 70‐point decrease in their CDAI score at week 4. Participants were randomized in a 1:1 ratio to receive either 40 mg eow or placebo, and were followed to week 52. </p> <p>The primary end point was clinical remission (CDAI &lt; 150) at week 52. Secondary end points included the number of participants in clinical remission every four weeks until week 52; number of participants with clinical response, defined as a decrease in CDAI score by 100 points or 70 points every four weeks until week 52; serum adalimumab levels; anti‐adalimumab antibody levels; and AEs. Investigators also reported the changes from baseline values in the CDAI, International Organization of Inflammatory Bowel Disease score (IOIBD), mental component summary and physical component summary of the Short Form‐36 Health Survey. </p> <p>In <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>, 51 participants who had an ileocolic resection two weeks prior to study enrolment were randomized to receive adalimumab 160 mg at week 0, 80 mg at week 2, followed by 40 mg eow (n = 16); azathioprine 2 mg/kg daily (n = 17); or mesalamine (5‐ASA) 3 g a day (n = 18), and were followed for 104 weeks. The primary end point was endoscopic recurrence (Rutgeerts score or i2 to i4) and clinical recurrence (based on investigators' own scale rating severity of symptoms from 1 to 4). Secondary end points included IBDQ score at 104 weeks. </p> <p>In <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>, 19 participants who had ileocolonic resection 45 days prior to study entry were randomized to receive adalimumab 160 mg at week 0, 80 mg at week 2, followed by 40 mg eow (n = 11); or 6‐mercaptopurine (6‐MP) 1.5 mg/kg daily (n = 8). The primary end point was the number of participants in endoscopic remission (Rutgeets i0 to i1) at week 24. Secondary outcomes included the number of participants in endoscopic remission (Rutgeets i0 to i1) at week 12; improvement in CDAI score; improvement in IBDQ score; improvement in fecal calprotectin levels; weight gain; and C‐reactive protein level. </p> </section> <section id="CD012877-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded four studies with reasons (<a href="./references#CD012877-bbs2-0007" title="De CruzP , KammMA , HamiltonAL , RitchieKJ , KrejanyEO , GorelikA , et al. Crohn's disease management after intestinal resection: A randomised trial. Lancet2014;385(9976):1406-17. ">De Cruz 2015</a>; <a href="./references#CD012877-bbs2-0008" title="DewintP , HansenBE , VerheyE , OldenburgB , HommesDW , PierikM , et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut2014;63(2):292-9. ">Dewint 2014</a>; <a href="./references#CD012877-bbs2-0009" title="FaubionWA , DubinskyM , RuemmeleFM , EscherJ , RoshJ , HyamsJS , et al. Long-term efficacy and safety of adalimumab in paediatric patients with Crohn’s disease. Inflammatory Bowel Diseases2017;23(3):453-60. ">Faubion 2017</a>; <a href="./references#CD012877-bbs2-0010" title="KhannaR , BresslerB , LevesqueBG , ZouG , StittLW , GreenbergGR , et al. Early combined immunosuppression for the management of Crohn's disease (REACT): A cluster randomised controlled trial. Lancet2015;386(10006):1825-34. ">Khanna 2015</a>; See <a href="./references#CD012877-sec-0085" title="">Characteristics of excluded studies</a> table). Two studies compared treatment algorithms for managing participants with CD (<a href="./references#CD012877-bbs2-0007" title="De CruzP , KammMA , HamiltonAL , RitchieKJ , KrejanyEO , GorelikA , et al. Crohn's disease management after intestinal resection: A randomised trial. Lancet2014;385(9976):1406-17. ">De Cruz 2015</a>; <a href="./references#CD012877-bbs2-0010" title="KhannaR , BresslerB , LevesqueBG , ZouG , StittLW , GreenbergGR , et al. Early combined immunosuppression for the management of Crohn's disease (REACT): A cluster randomised controlled trial. Lancet2015;386(10006):1825-34. ">Khanna 2015</a>), one study had both treatment and control groups on adalimumab therapy (<a href="./references#CD012877-bbs2-0008" title="DewintP , HansenBE , VerheyE , OldenburgB , HommesDW , PierikM , et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut2014;63(2):292-9. ">Dewint 2014</a>), and one study was an open‐label extension study with no control group (<a href="./references#CD012877-bbs2-0009" title="FaubionWA , DubinskyM , RuemmeleFM , EscherJ , RoshJ , HyamsJS , et al. Long-term efficacy and safety of adalimumab in paediatric patients with Crohn’s disease. Inflammatory Bowel Diseases2017;23(3):453-60. ">Faubion 2017</a>). We found one ongoing study, but no data were available for this review (<a href="./references#CD012877-bbs2-0011" title="NCT03464136. Safety and efficacy of adalimumab versus ustekinumab for one year (SEAVUE). clinicaltrials.gov/ct2/show/NCT03464136 (first received 13 March 2018). ">NCT03464136</a>). </p> </section> </section> <section id="CD012877-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the methodological quality of each study using the Cochrane 'Risk of bias' tool (<a href="./references#CD012877-bbs2-0026" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>), and we summarize our findings in <a href="#CD012877-fig-0002">Figure 2</a>. We attempted to contact study authors for additional information to clarify unclear items, but did not receive a response. </p> <div class="figure" id="CD012877-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012877-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012877-sec-0045"> <h4 class="title">Allocation</h4> <p>Four studies did not report on how participants were randomized to treatment groups or how allocation concealment was achieved. We rated these studies at unclear risk of bias for these domains (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). </p> </section> <section id="CD012877-sec-0046"> <h4 class="title">Blinding</h4> <p>Two studies did not report on how blinding was maintained for participants, personnel or outcome assessors throughout the study time period. We rated these studies at unclear risk of bias for these domains (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>). </p> </section> <section id="CD012877-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a> did not report on the number of participants who were initially randomized, so we could not determine the number of participants who had withdrawn during the study period. We rated the study at unclear risk of bias for this domain. </p> </section> <section id="CD012877-sec-0048"> <h4 class="title">Selective reporting</h4> <p>All of the included studies reported on all expected outcomes and were rated at low risk of bias for this domain (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). </p> </section> <section id="CD012877-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>None of the included studies appeared to have other potential sources of bias and were rated at low risk of bias for this domain (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). </p> </section> </section> <section id="CD012877-sec-0050"> <h3 class="title" id="CD012877-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD012877-tbl-0001"><b>Summary of findings 1</b> Adalimumab compared to placebo for maintenance of remission in Crohn's disease</a>; <a href="./full#CD012877-tbl-0002"><b>Summary of findings 2</b> Adalimumab compared to active comparator for maintenance of remission in Crohn's disease</a> </p> <section id="CD012877-sec-0051"> <h4 class="title">Adalimumab compared to placebo for maintenance of remission in CD</h4> <section id="CD012877-sec-0052"> <h5 class="title">Failure to maintain clinical remission at 52 to 56 weeks</h5> <p>Three studies (N = 683) reported on the number of participants who failed to maintain clinical remission at 52 to 56 weeks (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>). Two hundred and fifty‐five participants received 40 mg of adalimumab eow, 175 participants received 40 mg of adalimumab weekly and 253 participants received placebo. Overall, 59% (252/430) of participants receiving adalimumab failed to maintain clinical remission compared to 86% (217/253) in the placebo group (RR 0.70, 95% CI 0.64 to 0.77; <a href="./references#CD012877-fig-0003" title="">Analysis 1.1</a>). There was no heterogeneity detected for this outcome (I<sup>2</sup> = 0%). The GRADE analysis indicated that the overall certainty of evidence was high (<a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.69, 95% CI 0.63 to 0.76). A sensitivity analysis excluding the study at unclear risk of bias (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>) also had no impact on the overall results (RR 0.69, 95% CI 0.63 to 0.77). Due to insufficient data, we did not undertake any of the other planned sensitivity analyses for this outcome. </p> <p>In participants who received adalimumab 40 mg eow, 62% (157/255) of participants failed to maintain clinical remission at 52 to 56 weeks compared to 87% (138/159) of participants who received placebo (RR 0.73, 95% CI 0.65 to 0.81). In participants who received adalimumab 40 mg weekly, 54% (95/175) of participants who received adalimumab failed to maintain clinical remission compared to 84% (79/94) who received placebo (RR 0.66, 95% CI 0.57 to 0.77). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 1.07, df = 1, P = 0.30, I<sup>2</sup> = 6.6%; <a href="./references#CD012877-fig-0003" title="">Analysis 1.1</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0053"> <h5 class="title">Failure to maintain clinical remission at 24 to 26 weeks</h5> <p>Two studies (N = 554) reported on the number of participants who failed to maintain clinical remission at 24 to 26 weeks (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>). One hundred and ninety‐one participants received 40 mg of adalimumab eow, 175 participants received 40 mg of adalimumab weekly and 188 participants received placebo. Overall, 52% (192/366) of participants on adalimumab failed to maintain clinical remission at 24 to 26 weeks compared to 79% (149/188) of participants who received placebo (RR 0.66, 95% CI 0.52 to 0.83; <a href="./references#CD012877-fig-0004" title="">Analysis 1.2</a>). We detected moderate heterogeneity for this outcome (I<sup>2</sup> = 55%). The GRADE analysis indicates that the overall certainty of evidence was moderate, due to serious inconsistency (I<sup>2</sup> = 55%) (<a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.64, 95% CI 0.57 to 0.72). </p> <p>In participants who received adalimumab 40 mg eow, 56% (107/191) failed to maintain clinical remission at 24 to 26 weeks compared to 80% (75/94) of participants who received placebo (RR 0.55, 95% CI 0.23 to 1.32). In participants who received adalimumab 40 mg weekly, 52% (85/175) failed to maintain clinical remission at 24 to 26 weeks compared to 79% (74/94) of placebo participants (RR 0.39, 95% CI 0.08 to 1.81). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 0.15, df = 1, P = 0.70, I<sup>2</sup> = 0%; <a href="./references#CD012877-fig-0004" title="">Analysis 1.2</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0054"> <h5 class="title">Failure to maintain clinical response at 52 to 56 weeks</h5> <p>Four studies (N = 733) reported on the number of participants who failed to maintain clinical response at 52 to 56 weeks (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Two hundred and eighty participants received 40 mg of adalimumab eow, 175 participants received 40 mg of adalimumab weekly and 278 participants received placebo. Overall, 54% (244/455) of participants on adalimumab failed to maintain clinical response at 52 to 56 weeks compared to 81% (226/278) of participants who received placebo (RR 0.68, 95% CI 0.62 to 0.75; <a href="./references#CD012877-fig-0005" title="">Analysis 1.3</a>). We detected no heterogeneity for this outcome (I<sup>2</sup> = 0%), A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.67, 95% CI 0.61 to 0.74). A sensitivity analysis excluding the two studies with unclear risk of bias (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>) also had no impact on the overall results (RR 0.66, 95% CI 0.59 to 0.74). Due to insufficient data, we did not undertake any of the other planned sensitivity analyses for this outcome. </p> <p>In participants who received adalimumab 40 mg eow, 57% (160/280) of participants failed to maintain clinical response at 52 to 56 weeks compared to 82% (151/184) of participants who received placebo (RR 0.71, 95% CI 0.63 to 0.80). In participants who received adalimumab 40 mg weekly, 48% (84/175) failed to maintain clinical response compared to 80% (75/94) of placebo participants (RR 0.53, 95% CI 0.27 to 1.06). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 0.65, df = 1, P = 0.42, I<sup>2</sup> = 0%; <a href="./references#CD012877-fig-0005" title="">Analysis 1.3</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0055"> <h5 class="title">Failure to maintain clinical or endoscopic response at 52 to 56 weeks with prior TNF‐α antagonist exposure </h5> <p>Two studies (N = 302) reported the number of participants who failed to maintain clinical or endoscopic response at 52 to 56 weeks after having received prior TNF‐α antagonist therapy (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). Overall, 69% (129/186) of adalimumab participants failed to maintain clinical or endoscopic response compared with 93% (108/116) receiving placebo (RR 0.76, 95% CI 0.68 to 0.85; <a href="./references#CD012877-fig-0006" title="">Analysis 1.4</a>). We detected no heterogeneity for this outcome (I<sup>2</sup> = 0%). The GRADE analysis indicated that the overall certainty of evidence was moderate due to sparse data (237 events; <a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.76, 95% CI 0.68 to 0.84). A sensitivity analysis excluding the study with unclear risk of bias (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>) also had no impact on the overall results (RR 0.75, 95% CI 0.66 to 0.86). Due to insufficient data, we did not undertake any of the other planned sensitivity analyses for this outcome. </p> <p>In participants who received adalimumab 40 mg eow, 71% (82/115) of participants failed to maintain clinical or endoscopic response at 52 to 56 weeks compared to 95% (71/75) who received placebo (RR 0.77, 95% CI 0.67 to 0.88). In participants who received adalimumab 40 mg weekly, 66% (47/71) of participants who received adalimumab failed to maintain clinical or endoscopic response compared to 90% (37/41) of placebo participants (RR 0.73, 95% CI 0.60 to 0.89). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 0.17, df = 1, P = 0.68, I<sup>2</sup> = 0%; <a href="./references#CD012877-fig-0006" title="">Analysis 1.4</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0056"> <h5 class="title">Failure to maintain clinical response at 24 to 26 weeks</h5> <p>Two studies (N = 554) included failure to maintain clinical response at 24 to 26 weeks (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>). Overall, 44% (162/366) of participants who received adalimumab failed to maintain clinical response compared with 70% (132/188) of those who received placebo (RR 0.65, 95% CI 0.56 to 0.74; <a href="./references#CD012877-fig-0007" title="">Analysis 1.5</a>). We detected no heterogeneity for this outcome (I<sup>2</sup> = 0%). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.63, 95% CI 0.55 to 0.73). </p> <p>In participants who received adalimumab 40 mg eow, 45% (86/191) failed to maintain clinical response compared with 70% (66/94) who received placebo (RR 0.65, 95% CI 0.53 to 0.79). In participants who received adalimumab 40 mg weekly, 43% (76/175) failed to maintain clinical response compared to 70% (66/94) of participants who received placebo (RR 0.39, 95% CI 0.08 to 1.81). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 0.41, df = 1, P = 0.52, I<sup>2</sup> = 0%; <a href="./references#CD012877-fig-0007" title="">Analysis 1.5</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0057"> <h5 class="title">Failure to maintain endoscopic remission at 52 weeks</h5> <p>One study (N = 129) reported on the number of participants who failed to maintain endoscopic remission at 52 weeks (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). Seventy‐two per cent (46/64) of participants who received adalimumab failed to maintain endoscopic remission compared to 97% (63/65) of participants who received placebo (RR 0.74, 95% CI 0.63 to 0.87; <a href="./references#CD012877-fig-0008" title="">Analysis 1.6</a>). The GRADE analysis indicated that the overall certainty of evidence was moderate, due to sparse data (109 events; <a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD012877-sec-0058"> <h5 class="title">Failure to maintain endoscopic response at 52 weeks</h5> <p>One study (N = 123) reported on the number of participants who failed to maintain endoscopic response at 52 weeks (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). Seventy‐six per cent (47/62) of participants who received adalimumab failed to maintain endoscopic response compared to 100% (61/61) of participants who received placebo (RR 0.76, 95% CI 0.66 to 0.88; <a href="./references#CD012877-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD012877-sec-0059"> <h5 class="title">Failure to maintain histological remission at 52 weeks</h5> <p>One study (N = 129) reported on the number of participants who failed to maintain histologic remission at 52 weeks (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). Seventy‐six per cent (47/62) of participants who received adalimumab failed to maintain histological remission compared to 95% (62/65) of participants who received placebo (RR 0.79, 95% CI 0.68 to 0.92; <a href="./references#CD012877-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD012877-sec-0060"> <h5 class="title">Adverse events</h5> <p>Four studies (N = 1012) reported on AEs (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Overall, 87% (561/643) of participants who received adalimumab reported an AE compared with 85% (315/369) of participants who received placebo (RR 1.01, 95% CI 0.94 to 1.09; <a href="./references#CD012877-fig-0011" title="">Analysis 1.9</a>). We detected some heterogeneity for this outcome (I<sup>2</sup> = 40%). The GRADE analysis indicates that the overall certainty of the evidence was high (<a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 1.03, 95% CI 0.97 to 1.08). A sensitivity analysis excluding the two studies with unclear risk of bias (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>) also had no impact on the overall results (RR 0.99, 95% CI 0.90 to 1.08). Due to insufficient data, we did not undertake any of the other planned sensitivity analyses for this outcome. Some commonly‐reported AEs included CD aggravation, arthralgia, nasopharyngitis, urinary tract infections, headache, nausea, fatigue and abdominal pain. </p> <p>In participants who received adalimumab 40 mg eow, 89% (327/368) of participants experienced an AE compared with 86% (196/229) of participants who received placebo (RR 1.03, 95% CI 0.93 to 1.14). In participants who received adalimumab 40 mg weekly, 85% (234/275) of participants experienced an AE compared with 85% (119/140) of participants who received placebo (RR 0.94, 95% CI 0.76 to 1.17). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 0.52, df = 1, P = 0.47, I² = 0%; <a href="./references#CD012877-fig-0011" title="">Analysis 1.9</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0061"> <h5 class="title">Serious adverse events</h5> <p>Four studies (N = 1012) reported SAEs (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). SAEs were seen in 8% (52/643) of participants who received adalimumab and 14% (53/369) of participants who received placebo (RR 0.56, 95% CI 0.39 to 0.80; <a href="./references#CD012877-fig-0012" title="">Analysis 1.10</a>). We detected no heterogeneity for this outcome (I<sup>2</sup> = 0%). The GRADE analysis indicates that the overall certainty of evidence was moderate, due to sparse data (105 events; <a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.55, 95% CI 0.38 to 0.79). A sensitivity analysis excluding the two studies at unclear risk of bias (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>) also had no impact on the overall results (RR 0.56, 95% CI 0.38 to 0.82). Due to insufficient data, we did not undertake any of the other planned sensitivity analyses for this outcome. The reported SAEs included infectious complications including tuberculosis, abscess formation and wound infections, multiple sclerosis, and pulmonary embolism. </p> <p>In participants who received adalimumab 40 mg eow, 8% (31/368) of participants experienced a SAE compared to 14% (32/229) of participants who received placebo (RR 0.59, 95% CI 0.36 to 0.94). In participants who received adalimumab 40 mg weekly, 8% (21/275) experienced a SAE compared with 15% (21/140) who received placebo (RR 0.52, 95% CI 0.29 to 0.91). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 0.11, df = 1, P = 0.73, I<sup>2</sup> = 0%; <a href="./references#CD012877-fig-0012" title="">Analysis 1.10</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> <section id="CD012877-sec-0062"> <h5 class="title">Withdrawal due to adverse events</h5> <p>Four studies (N = 1012) reported on withdrawal due to AEs (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Withdrawals due to AEs were reported in 7% (45/643) of adalimumab participants compared to 13% (48/369) of placebo participants (RR 0.59, 95% CI 0.38 to 0.91; <a href="./references#CD012877-fig-0013" title="">Analysis 1.11</a>). We detected low heterogeneity for this outcome (I<sup>2</sup> = 13%). The GRADE analysis indicates that the overall certainty of evidence was moderate due to sparse data (93 events; <a href="./full#CD012877-tbl-0001">summary of findings Table 1</a>). A sensitivity analysis using a fixed‐effect model had no impact on the overall results (RR 0.57, 95% CI 0.39 to 0.83). A sensitivity analysis excluding the two studies with unclear risk of bias (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>) had no major impact on the overall results (RR 0.44, 95% CI 0.28 to 0.69). Due to insufficient data, we did not undertake any of the other planned sensitivity analyses for this outcome. AEs leading to withdrawal included a flare of CD and infectious complications. </p> <p>In participants who received adalimumab 40 mg eow, 9% (32/368) of participants withdrew due to an AE compared to 13% (30/229) of participants who received placebo (RR 0.73, 95% CI 0.43 to 1.21). In participants who received adalimumab 40 mg weekly, 5% (13/275) withdrew due to an AE compared with 13% (18/140) who received placebo (RR 0.37, 95% CI 0.19 to 0.73). The test for subgroup differences by dosing regimen showed no difference between the regimens (test for subgroup differences Chi<sup>2</sup> = 2.43, df = 1, P = 0.12, I<sup>2</sup> = 58.9%; <a href="./references#CD012877-fig-0013" title="">Analysis 1.11</a>). We did not conduct any of the other planned subgroup analyses due to insufficient data. </p> </section> </section> <section id="CD012877-sec-0063"> <h4 class="title">Adalimumab compared to active comparator for maintenance of remission in CD</h4> <section id="CD012877-sec-0064"> <h5 class="title">Failure to maintain clinical response at 104 weeks</h5> <p>One study (N = 51) reported on failure to maintain clinical response at 104 weeks in participants who received either adalimumab, azathioprine or mesalamine (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>). Thirteen per cent (2/16) of participants who received adalimumab failed to maintain clinical response compared with 54% (19/35) of participants who received azathioprine or mesalamine (RR 0.23, 95% CI 0.06 to 0.87; <a href="./references#CD012877-fig-0014" title="">Analysis 2.1</a>). </p> </section> <section id="CD012877-sec-0065"> <h5 class="title">Failure to maintain endoscopic remission at 104 weeks</h5> <p>One study (N = 51) reported on failure to maintain endoscopic remission at 104 weeks in participants who received either adalimumab, azathioprine or mesalamine (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>). Six per cent (1/16) of participants who received adalimumab failed to maintain endoscopic remission compared with 57% (20/35) of participants who received azathioprine or mesalamine (RR 0.11, 95% CI 0.02 to 0.75; <a href="./references#CD012877-fig-0015" title="">Analysis 2.2</a>). The GRADE analysis indicates that the certainty of evidence was very low due to unclear risk of bias and very sparse data (<a href="./full#CD012877-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012877-sec-0066"> <h5 class="title">Failure to maintain endoscopic remission at 24 weeks</h5> <p>One study (N = 19) reported on failure to maintain endoscopic response at 24 weeks in participants who received either adalimumab or 6‐MP (<a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>). Nine per cent (1/11) of participants who received adalimumab failed to maintain endoscopic remission compared with 50% (4/8) of participants who received 6‐MP (RR 0.18, 95% CI 0.02 to 1.33; <a href="./references#CD012877-fig-0016" title="">Analysis 2.3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012877-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012877-sec-0067"></div> <section id="CD012877-sec-0068"> <h3 class="title" id="CD012877-sec-0068">Summary of main results</h3> <p>This review includes six studies (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Four of these studies are randomized placebo‐controlled trials that examined the efficacy of adalimumab for maintaining remission in participants with quiescent CD (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Two of the studies are active comparator trials that examined the efficacy of adalimumab for maintaining surgically‐induced remission in CD (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>). <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a> compared adalimumab to azathioprine or mesalamine. <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a> compared adalimumab to 6‐MP. </p> <p>All studies used validated outcome measures for study end points. Clinical remission was reported using a CDAI score of 150 or less in four studies (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). Histological end points were reported using both CDEIS and SES‐CD scores (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). Two studies examined the efficacy of adalimumab in the postoperative course (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>), using the Rutgeerts score to report clinical recurrence at the ileocolic anastomosis. </p> <p>Three studies reported on the proportion of participants who failed to maintain clinical remission at 52 to 56 weeks (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>). Overall, 59% (252/430) of participants who received adalimumab failed to maintain clinical remission compared to 86% (217/253) in the placebo group (high‐certainty evidence). Subgroup analyses based on dose showed that weekly dosing and bi‐weekly dosing of adalimumab were both effective, with minimal difference in clinical remission rates seen between the two dosing regimens. Although these relapse rates are fairly high it should be noted that these participants had moderate‐to‐severe Crohn’s disease prior to induction of remission and many of these participants had failed treatment with other biologics (e.g. infliximab) or standard maintenance therapies (e.g. azathioprine or 6‐mercaptopurine) prior to participating in the RCTs. An optimal maintenance therapy in people with CD with these characteristics has yet to be identified. </p> <p>High‐certainty evidence suggests that there was no difference in adverse events (AEs) between the adalimumab and placebo groups. Eighty‐seven per cent (561/643) of participants who received adalimumab reported an AE compared with 85% (315/369) of participants who received placebo. Moderate‐certainty evidence suggests there was no difference in serious adverse event (SAE) rates between groups. Eight per cent (52/643) of participants who received adalimumab experienced SAEs compared with 14% (53/369) of participants who received placebo. Moderate‐certainty evidence suggests there was no difference between the groups in the number of participants who withdrew due to AEs. Seven per cent (45/643) of adalimumab participants withdrew due to AEs compared to 13% (48/369) of placebo participants. </p> <p><a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a> reported on endoscopic and histologic end points in participants who had received adalimumab compared with participants who received placebo. <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a> found that 72% (46/64) of participants who received adalimumab failed to maintain endoscopic remission at 52 weeks compared to 97% (63/65) of participants who received placebo. <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a> also reported that 76% (47/62) of participants who received adalimumab failed to maintain histological remission at 52 weeks compared to 95% (62/65) of participants who received placebo. We could draw minimal conclusions from these data, as no other studies reported on these important end points. </p> <p>Two studies reported on the proportion of participants who failed to maintain clinical or endoscopic response at 52 to 56 weeks after having prior TNF‐α antagonist therapy (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). Overall, 69% (129/186) of adalimumab participants failed to maintain clinical or endoscopic response compared with 93% (108/116) receiving placebo (moderate‐certainty evidence). </p> <p>Two small studies reported on the proportion of participants who failed to maintain clinical and endoscopic end points, following surgical resection for CD (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>, <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>). Adalimumab therapy was compared with either azathioprine, mesalamine or 6‐mercaptopurine. <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a> reported that 13% (2/16) of participants who received adalimumab failed to maintain clinical response at 104 weeks, compared with 54% (19/35) of participants who received azathioprine or mesalamine. Also, six per cent (1/16) of participants who received adalimumab failed to maintain endoscopic remission at 104 weeks compared with 57% (20/35) of participants who received azathioprine or mesalamine (very low‐certainty evidence). <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a> reported that 9% (1/11) of participants who received adalimumab failed to maintain endoscopic remission at 24 weeks compared with 50% (4/8) of participants who received azathioprine. Overall, data surrounding maintenance therapy in the postoperative course are of very low certainty, and further research should be done to determine the best treatment course postoperatively. </p> </section> <section id="CD012877-sec-0069"> <h3 class="title" id="CD012877-sec-0069">Overall completeness and applicability of evidence</h3> <p>The results of this Cochrane Review are applicable to people with moderate‐to‐severe CD (CDAI 220 to 450) who are in remission. Study participants included people who had previous treatment with infliximab and had lost response or had become intolerant to the drug, and people who were TNF‐α‐naïve. However, the overall evidence cannot be considered complete. The overall completeness of the data pertaining to both histological and endoscopic end points is lacking. Only one study reported on both endoscopic and histologic outcomes (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>). These outcomes are of interest to clinicians, and further evidence in this area would be required to draw definitive conclusions about the certainty of this evidence. </p> <p>Two small studies reported on the course of treatment in participants who had recently had a surgical resection (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>). These studies were small and reported on few outcomes. They compared adalimumab therapy to different active drugs, including azathioprine, mesalamine and 6‐mercaptopurine. Minimal conclusions can therefore be drawn from these data and the evidence base in the postoperative setting cannot be considered complete. </p> </section> <section id="CD012877-sec-0070"> <h3 class="title" id="CD012877-sec-0070">Quality of the evidence</h3> <p>We judged two of the included studies to be at low risk of bias (<a href="./references#CD012877-bbs2-0001" title="ColombelJ , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology2007;132(1):52-65. ColombelJF , SandbornWJ , CastilloMM , ZhouQ , ThakkarRB . Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials. Gut2012;61:A229. ColombelJF , SandbornWJ , RutgeertsP , KammMA , YuAP , WuEQ , et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. American Journal of Gastroenterology2009;104(5):1170-9. ColombelJF , SchwartzDA , SandbornWJ , KammMA , D'HaensG , RutgeertsP , et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut2009;58(7):940-8. ColombelJF . The CHARM trial of adalimumab in Crohn's disease. Gastroenterology and Hepatology2006;2(7):486-8. FeaganBG , PanaccioneR , SandbornWJ , D'HaensGR , SchreiberS , RutgeertsPJ , et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135(5):1493-9. LoftusE , YangM , MulaniP , ChaoJ . Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM. American Journal of Gastroenterology2011;106:S449-S50. LoftusEV , FeaganBG , ColombelJF , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. American Journal of Gastroenterology2008;103(12):3132-41. RubinDT , MulaniP , ChaoJ , PollackPF , BensimonAG , YuAP , et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflammatory Bowel Diseases2012;18(5):818-25. SchreiberS , ReinischW , ColombelJF , SandbornW , RobinsonA , HuangB , et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis2012;6:S106. VermeireS , ColombelJ , RobinsonAM , HuangB , ThakkarRB , PollackPF . Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use. Journal of Crohn's and Colitis2011;5(1):S68-S9. WasvaryHJ . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Diseases of the Colon and Rectum2007;50(8):1291. ">Colombel 2007</a>; <a href="./references#CD012877-bbs2-0003" title="ColombelJ , RutgeertsP , SandbornWJ , ReinischW , Loftus EV Jr, TangJ , et al. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease. Journal of Crohn's &amp; Colitis2011;5(1):S88. SandbornWJ , HanauerSB , RutgeertsP , FedorakRN , LulcasM , MacIntoshDG , et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut2007;56(9):1232-9. ">Sandborn 2007</a>). Four studies were rated at unclear risk of bias for random sequence generation and allocation concealment (<a href="./references#CD012877-bbs2-0002" title="ColombelJ , SandbornWJ , LouisE , PanaccioneR , YangM , ChaoJ , et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Journal of Crohn's and Colitis2011;5(1):S41-S2. ColombelJ , SchreiberS , RutgeertsP , SandbornW , YangM , LomaxK , et al. Effect of disease duration on 'deep remission': Results from the EXTEND trial. Inflammatory Bowel Diseases2011;17:S44. ColombelJF , RutgeertsP , SandbornW , YangM , LomaxK , PollackP , et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend. American Journal of Gastroenterology2010;105:S434-S5. FeaganB , SandbornWJ , RutgeertsP , LevesqueBG , KhannaR , HuangB , et al. Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data. Inflammatory Bowel Diseases2018;24(5):932-42. ReinischW , ColombelJ , D’HaensG , SandbornWJ , RutgeertsP , GeboesK , et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: Results from the EXTEND Trial. Journal of Crohn's &amp; Colitis2017;11(4):425-34. ReinischW , ColombelJF , D'HaensG , SandbornW , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. American Journal of Gastroenterology2014;109:S475. ReinischW , ColombelJF , D'HaensG , SandbornWJ , RutgeertsP , PeterssonJ , et al. Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend. United European Gastroenterology Journal2014;1:A537. RutgeertsP , ReinischW , SandbornWJ , D'HaensG , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S30-S1. RutgeertsP , Van AsscheG , SandbornWJ , WolfDC , GeboesK , ColombelJF , et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142(5):1102-11. RutgeertsPJ , ReinischW , SandbornW , D'HaensGR , ColombelJF , PeterssonJ , et al. Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend. Gastroenterology2014;1:S585. SandbornW , ColombelJF , LomaxK , PollackP , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND. American Journal of Gastroenterology2010;105:S442-S3. SandbornW , ColombelJF , PanaccioneR , LouisE , YangM , PollackP , et al. Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn's &amp; Colitis2012;6:S112. SandbornW , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend. Gastroenterology2014;1:S589. SandbornWJ , ColombelJF , LomaxKG , PollackPF , ThakkarR , CamezA , et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend. Gut2011;60:A136-A7. SandbornWJ , WolfD , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Crohn's &amp; Colitis2014;8:S306-S7. SandbornWJ , WolfDC , ColombelJF , PanesJ , EichnerS , IezziA , et al. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND. Journal of Gastroenterology and Hepatology2014;29:118. ">Rutgeerts 2012</a>; <a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>; <a href="./references#CD012877-bbs2-0006" title="WatanabeM , HibiT , LomaxKG , PaulsonSK , ChaoJ , AlamMS , et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's &amp; Colitis2012;6(2):160-73. ">Watanabe 2012</a>). We rated two studies at unclear risk of bias for blinding (<a href="./references#CD012877-bbs2-0004" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Digestive and Liver Disease2013;45:S94-S5. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. Gastroenterology2013;1:S21. SavarinoE , BodiniG , DulbeccoP , SavarinoV . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial. United European Gastroenterology Journal2013;1:A17. ">Savorino 2013</a>; <a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>), and one study at unclear risk of bias for incomplete outcome data (<a href="./references#CD012877-bbs2-0005" title="ScapaE , Fliss-IsakovN , TulchinskyH , YanaiH , WhiteI , DotanI , et al. Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study. United European Gastroenterology Journal2018;6:A458. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteI , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Journal of Crohn's &amp; Colitis2015;9:S303-S4. ScapaE , MaharshakN , KarivY , Ben-HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;1:S240-S1. ">Scapa 2015</a>). For the placebo‐controlled studies, the GRADE analysis for the primary outcome of failure to maintain clinical remission at 52 to 56 weeks was high, and was moderate for failure to maintain clinical remission at 24 to 26 weeks. The GRADE rating for the other secondary outcomes was moderate, except for adverse events, which we rated as high‐certainty evidence. For the studies comparing adalimumab to azathioprine, mesalamine or 6‐mercaptopurine in the postoperative setting the overall certainty of the evidence for the secondary outcome of failure to maintain endoscopic remission at 104 weeks was very low. The studies in the postoperative setting did not report on any of our other prespecified primary or secondary outcomes. </p> </section> <section id="CD012877-sec-0071"> <h3 class="title" id="CD012877-sec-0071">Potential biases in the review process</h3> <p>We conducted a comprehensive literature review to help ensure that we included all relevant studies. Two review authors independently assessed for study inclusion, extracted data and assessed for risks of bias. The main limitation of this review is the lack of data available for endoscopic and histological end points. </p> </section> <section id="CD012877-sec-0072"> <h3 class="title" id="CD012877-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>One other systematic review and meta‐analysis has recently been published that also discusses the efficacy of adalimumab for maintenance of remission in CD. <a href="./references#CD012877-bbs2-0033" title="SinghS , FumeryM , SandbornW , MuradMH . Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Alimentary Pharmacology &amp; Therapeutics2018;48(4):394–409.">Singh 2018</a> assessed the efficacy and safety of first‐ and second‐line TNF‐α antagonists for treatment of moderate‐to‐severe CD. The results for failure to maintain remission at 52 to 56 agree with the results of our review. However, <a href="./references#CD012877-bbs2-0033" title="SinghS , FumeryM , SandbornW , MuradMH . Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Alimentary Pharmacology &amp; Therapeutics2018;48(4):394–409.">Singh 2018</a> focused on identifying which TNF‐α antagonists should be considered for first‐ and second‐line therapy, a question which we did not address in this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012877-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012877-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012877-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 1: Failure to maintain clinical remission at 52 to 56 weeks" data-id="CD012877-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 1: Failure to maintain clinical remission at 52 to 56 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 2: Failure to maintain clinical remission at 24 to 26 weeks" data-id="CD012877-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 2: Failure to maintain clinical remission at 24 to 26 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 3: Failure to maintain clinical response at 52 to 56 weeks" data-id="CD012877-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 3: Failure to maintain clinical response at 52 to 56 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 4: Failure to maintain clinical or endoscopic response at 52 to 56 weeks with prior TNF antagonist exposure" data-id="CD012877-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 4: Failure to maintain clinical or endoscopic response at 52 to 56 weeks with prior TNF antagonist exposure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 5: Failure to maintain clinical response at 24 to 26 weeks" data-id="CD012877-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 5: Failure to maintain clinical response at 24 to 26 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 6: Failure to maintain endoscopic remission at 52 weeks" data-id="CD012877-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 6: Failure to maintain endoscopic remission at 52 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 7: Failure to maintain endoscopic response at 52 weeks" data-id="CD012877-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 7: Failure to maintain endoscopic response at 52 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 8: Failure to maintain histological remission at 52 weeks" data-id="CD012877-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 8: Failure to maintain histological remission at 52 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 9: Adverse events" data-id="CD012877-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 9: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 10: Serious adverse events" data-id="CD012877-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 10: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adalimumab versus placebo, Outcome 11: Withdrawals due to adverse events" data-id="CD012877-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Adalimumab versus placebo, Outcome 11: Withdrawals due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adalimumab versus active comparator, Outcome 1: Failure to maintain clinical response at 104 weeks" data-id="CD012877-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Adalimumab versus active comparator, Outcome 1: Failure to maintain clinical response at 104 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adalimumab versus active comparator, Outcome 2: Failure to maintain endoscopic remission at 104 weeks" data-id="CD012877-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Adalimumab versus active comparator, Outcome 2: Failure to maintain endoscopic remission at 104 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012877-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/urn:x-wiley:14651858:media:CD012877:CD012877-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adalimumab versus active comparator, Outcome 3: Failure to maintain endoscopic remission at 24 weeks" data-id="CD012877-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_t/tCD012877-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Adalimumab versus active comparator, Outcome 3: Failure to maintain endoscopic remission at 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/media/CDSR/CD012877/image_n/nCD012877-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012877-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Adalimumab compared to placebo for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab compared to placebo for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with quiescent Crohn's disease<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> Adalimumab (40 mg/week or 40 mg every other week)<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Adalimumab</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain clinical remission</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.64 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>683<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission defined as a CDAI &lt; 150</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>858 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000<br/>(549 to 660) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain clinical remission</p> <p>Follow‐up: 24 to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.52 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>554<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission defined as a CDAI &lt; 150</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>793 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>523 per 1000<br/>(412 to 658) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to maintain endoscopic remission</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>969 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>717 per 1000</p> <p>(611 to 843)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.74</p> <p>(0.63 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic remission defined as an absence of mucosal ulceration</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1012<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Commonly‐reported adverse events included CD aggravation, arthralgia, nasopharyngitis, urinary tract infections, headache, nausea, fatigue and abdominal pain </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>854 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>862 per 1000<br/>(802 to 930) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/>(0.39 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1012<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported serious adverse events included infectious complications including tuberculosis, abscess formation and wound infections, multiple sclerosis, pulmonary embolism </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/>(56 to 115) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawals due to adverse events</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.38 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1012<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal included flare of CD, infectious complications</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000<br/>(49 to 118) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure</p> <p>Follow‐up: 52 to 56 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/>(0.68 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>302<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response defined as decrease in baseline CDAI score of ≥ 100. Endoscopic response defined as mucosal healing seen at time of endoscopy </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>708 per 1000<br/>(633 to 791) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious inconsistency (I<sup>2</sup> = 55%).<br/><sup>b</sup>Downgraded by one level due to sparse data (109 events).<br/><sup>c</sup>Downgraded by one level due to sparse data (105 events).<br/><sup>d</sup>Downgraded by one level due to sparse data (93 events).<br/><sup>e</sup>Downgraded by one level due to sparse data (237 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Adalimumab compared to placebo for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012877-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Adalimumab compared to active comparator for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab compared to active comparator for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with quiescent Crohn's disease (ileocolic resection)<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> Adalimumab (40 mg every other week)<br/><b>Comparison:</b> Active comparator ‐ azathioprine (2 mg/kg/day), mesalamine (3 g/day), or 6‐mercaptopurine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with active comparator</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Adalimumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure to maintain clinical remission</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to maintain endoscopic remission</p> <p>Follow‐up: 104 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.11<br/>(0.02 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic remission defined as Rutgeerts score &lt; i2</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/>(11 to 429) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to unclear risk of bias.<br/><sup>b</sup>Downgraded two levels due to very sparse data (21 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Adalimumab compared to active comparator for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/full#CD012877-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012877-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adalimumab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure to maintain clinical remission at 52 to 56 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.64, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.65, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.57, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Failure to maintain clinical remission at 24 to 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.23, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Failure to maintain clinical response at 52 to 56 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.62, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.63, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.27, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Failure to maintain clinical or endoscopic response at 52 to 56 weeks with prior TNF antagonist exposure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.68, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.60, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Failure to maintain clinical response at 24 to 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.53, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Failure to maintain endoscopic remission at 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Failure to maintain endoscopic response at 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Failure to maintain histological remission at 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.39, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.36, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.29, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Dose 40 mg every other week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.43, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Dose 40 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.19, 0.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adalimumab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012877-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adalimumab versus active comparator</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure to maintain clinical response at 104 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Failure to maintain endoscopic remission at 104 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Failure to maintain endoscopic remission at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adalimumab versus active comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012877.pub2/references#CD012877-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012877.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012877-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012877-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012877-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012877-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012877-note-0008">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012877\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012877\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012877\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012877\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012877\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012877.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012877.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012877.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012877.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012877.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726070166"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012877.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726070170"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012877.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8aa1f8039379',t:'MTc0MDcyNjA3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 